[144] BioCryst Pharmaceuticals Inc SEC Filing
BioCryst Pharmaceuticals (BCRX) Form 144 notifies a proposed sale of 70,000 common shares through Fidelity Brokerage Services with an aggregate market value of $595,870.74. The shares are scheduled for sale on 08/13/2025 on NASDAQ and come from a reported total outstanding share count of 209,920,430.
The filing shows the shares derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020, with the consideration listed as cash. The filer reports Nothing to Report for sales in the past three months and includes the standard representation that no undisclosed material adverse information is known to the seller.
BioCryst Pharmaceuticals (BCRX) Il Form 144 segnala una proposta di vendita di 70,000 azioni ordinarie tramite Fidelity Brokerage Services per un valore di mercato complessivo di $595,870.74. Le azioni sono programmate per la vendita il 08/13/2025 sul NASDAQ e provengono da un totale di azioni in circolazione segnalato di 209,920,430.
La comunicazione indica che le azioni derivano da opzioni su azioni: 30,000 da un'opzione concessa il 05/29/2019 e 40,000 da un'opzione concessa il 05/12/2020; il corrispettivo 猫 indicato come contanti. Il dichiarante riferisce Nulla da segnalare per vendite negli ultimi tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
BioCryst Pharmaceuticals (BCRX) El Formulario 144 notifica una propuesta de venta de 70,000 acciones ordinarias a trav茅s de Fidelity Brokerage Services por un valor de mercado agregado de $595,870.74. Las acciones est谩n programadas para su venta el 08/13/2025 en NASDAQ y proceden de un total de acciones en circulaci贸n declarado de 209,920,430.
La presentaci贸n muestra que las acciones provienen de opciones sobre acciones: 30,000 de una opci贸n otorgada el 05/29/2019 y 40,000 de una opci贸n otorgada el 05/12/2020, con la contraprestaci贸n indicada como efectivo. El declarante informa Nada que reportar respecto a ventas en los 煤ltimos tres meses e incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
BioCryst Pharmaceuticals (BCRX) Form 144電� Fidelity Brokerage Services毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $595,870.74鞚� 70,000 氤错喌欤� 毵り皝 鞓堨爼鞛勳潉 韱奠頃╇媹雼�. 頃措嫻 欤检嫕鞚� 08/13/2025 NASDAQ鞐愳劀 毵り皝霅� 鞓堨爼鞚措┌, 氤搓碃霅� 齑� 氚滍枆 欤检嫕靾橂姅 209,920,430鞛呺媹雼�.
鞁犼碃靹滌棎 霐半ゴ氅� 欤检嫕鞚� 鞀ろ啞鞓奠厴鞐愳劀 牍勲’霅橃棃鞙茧┌: 30,000欤茧姅 05/29/2019鞐� 攵�鞐悳 鞓奠厴, 40,000欤茧姅 05/12/2020鞐� 攵�鞐悳 鞓奠厴鞐愳劀 臧侁皝 氚滌儩頄堨溂氅� 雽�旮堨潃 顺勱笀鞙茧 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈 臧� 毵り皝鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 氤搓碃頃橂┌, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹鞚� 韽暔頃╇媹雼�.
BioCryst Pharmaceuticals (BCRX) Le formulaire 144 signale une proposition de vente de 70,000 actions ordinaires via Fidelity Brokerage Services pour une valeur de march茅 totale de $595,870.74. Les actions sont programm茅es pour vente le 08/13/2025 sur le NASDAQ et proviennent d'un nombre total d'actions en circulation d茅clar茅 de 209,920,430.
Le d茅p么t indique que les actions proviennent d'options sur actions : 30,000 provenant d'une option accord茅e le 05/29/2019 et 40,000 d'une option accord茅e le 05/12/2020, la contrepartie 茅tant indiqu茅e comme 别蝉辫猫肠别蝉. Le d茅clarant indique Rien 脿 d茅clarer pour les ventes au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable significative non divulgu茅e.
BioCryst Pharmaceuticals (BCRX) Form 144 meldet einen geplanten Verkauf von 70,000 Stammaktien 眉ber Fidelity Brokerage Services mit einem Gesamtkurswert von $595,870.74. Die Aktien sollen am 08/13/2025 an der NASDAQ verkauft werden und stammen aus einer gemeldeten Gesamtanzahl ausstehender Aktien von 209,920,430.
Die Einreichung zeigt, dass die Aktien aus Aktienoptionen stammen: 30,000 aus einer am 05/29/2019 gew盲hrten Option und 40,000 aus einer am 05/12/2020 gew盲hrten Option; die Gegenleistung ist als Bargeld angegeben. Der Einreicher berichtet Nichts zu melden f眉r Verk盲ufe in den letzten drei Monaten und enth盲lt die 眉bliche Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.
- None.
- None.
Insights
TL;DR Routine Form 144 for 70,000 shares, representing 鈮�0.033% of outstanding shares; likely immaterial to market capitalization.
The Form 144 discloses a proposed sale of 70,000 common shares through Fidelity with an aggregate market value of $595,870.74 and an outstanding share count of 209,920,430. Based on those figures, the proposed sale represents roughly 0.033% of outstanding shares, a very small fraction unlikely to move the stock materially on its own. The filing indicates the shares stem from option grants dated 05/29/2019 (30,000 shares) and 05/12/2020 (40,000 shares) and lists payment as cash. The filer reports no sales in the past three months.
TL;DR Disclosure appears procedural and consistent with Rule 144; some form fields are unpopulated in the provided text.
The notice supplies required transaction details鈥攂roker, number of shares, aggregate value, acquisition provenance (stock options), and planned sale date鈥攃onsistent with compliance expectations for a Rule 144 notice. In the version provided, heading fields such as the issuer name block and the date/signature lines are shown but contain no populated values, as displayed in the content. That omission may reflect how the content was captured rather than substance about the sale itself. Overall, the disclosure is routine and the filing is not a material corporate event.
BioCryst Pharmaceuticals (BCRX) Il Form 144 segnala una proposta di vendita di 70,000 azioni ordinarie tramite Fidelity Brokerage Services per un valore di mercato complessivo di $595,870.74. Le azioni sono programmate per la vendita il 08/13/2025 sul NASDAQ e provengono da un totale di azioni in circolazione segnalato di 209,920,430.
La comunicazione indica che le azioni derivano da opzioni su azioni: 30,000 da un'opzione concessa il 05/29/2019 e 40,000 da un'opzione concessa il 05/12/2020; il corrispettivo 猫 indicato come contanti. Il dichiarante riferisce Nulla da segnalare per vendite negli ultimi tre mesi e include la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
BioCryst Pharmaceuticals (BCRX) El Formulario 144 notifica una propuesta de venta de 70,000 acciones ordinarias a trav茅s de Fidelity Brokerage Services por un valor de mercado agregado de $595,870.74. Las acciones est谩n programadas para su venta el 08/13/2025 en NASDAQ y proceden de un total de acciones en circulaci贸n declarado de 209,920,430.
La presentaci贸n muestra que las acciones provienen de opciones sobre acciones: 30,000 de una opci贸n otorgada el 05/29/2019 y 40,000 de una opci贸n otorgada el 05/12/2020, con la contraprestaci贸n indicada como efectivo. El declarante informa Nada que reportar respecto a ventas en los 煤ltimos tres meses e incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n adversa material no divulgada.
BioCryst Pharmaceuticals (BCRX) Form 144電� Fidelity Brokerage Services毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $595,870.74鞚� 70,000 氤错喌欤� 毵り皝 鞓堨爼鞛勳潉 韱奠頃╇媹雼�. 頃措嫻 欤检嫕鞚� 08/13/2025 NASDAQ鞐愳劀 毵り皝霅� 鞓堨爼鞚措┌, 氤搓碃霅� 齑� 氚滍枆 欤检嫕靾橂姅 209,920,430鞛呺媹雼�.
鞁犼碃靹滌棎 霐半ゴ氅� 欤检嫕鞚� 鞀ろ啞鞓奠厴鞐愳劀 牍勲’霅橃棃鞙茧┌: 30,000欤茧姅 05/29/2019鞐� 攵�鞐悳 鞓奠厴, 40,000欤茧姅 05/12/2020鞐� 攵�鞐悳 鞓奠厴鞐愳劀 臧侁皝 氚滌儩頄堨溂氅� 雽�旮堨潃 顺勱笀鞙茧 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈 臧� 毵り皝鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 氤搓碃頃橂┌, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹鞚� 韽暔頃╇媹雼�.
BioCryst Pharmaceuticals (BCRX) Le formulaire 144 signale une proposition de vente de 70,000 actions ordinaires via Fidelity Brokerage Services pour une valeur de march茅 totale de $595,870.74. Les actions sont programm茅es pour vente le 08/13/2025 sur le NASDAQ et proviennent d'un nombre total d'actions en circulation d茅clar茅 de 209,920,430.
Le d茅p么t indique que les actions proviennent d'options sur actions : 30,000 provenant d'une option accord茅e le 05/29/2019 et 40,000 d'une option accord茅e le 05/12/2020, la contrepartie 茅tant indiqu茅e comme 别蝉辫猫肠别蝉. Le d茅clarant indique Rien 脿 d茅clarer pour les ventes au cours des trois derniers mois et inclut la d茅claration standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable significative non divulgu茅e.
BioCryst Pharmaceuticals (BCRX) Form 144 meldet einen geplanten Verkauf von 70,000 Stammaktien 眉ber Fidelity Brokerage Services mit einem Gesamtkurswert von $595,870.74. Die Aktien sollen am 08/13/2025 an der NASDAQ verkauft werden und stammen aus einer gemeldeten Gesamtanzahl ausstehender Aktien von 209,920,430.
Die Einreichung zeigt, dass die Aktien aus Aktienoptionen stammen: 30,000 aus einer am 05/29/2019 gew盲hrten Option und 40,000 aus einer am 05/12/2020 gew盲hrten Option; die Gegenleistung ist als Bargeld angegeben. Der Einreicher berichtet Nichts zu melden f眉r Verk盲ufe in den letzten drei Monaten und enth盲lt die 眉bliche Erkl盲rung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.
FAQ
How many BioCryst (BCRX) shares are proposed to be sold in this Form 144?
When is the approximate sale date for the shares listed on the Form 144?
Which broker and exchange are referenced for the proposed sale?
How were the securities acquired according to the filing?
Has the filer sold any securities of the issuer in the past three months?
